Evidence map›Paper›PMID 42677115›Full record

ArticleNigerian medical journal : journal of the Nigeria Medical Association

Prostate Cancer Management in Nigeria: A mini-review of up-to-date treatment options.

Emmanuel O Oisakede

Abstract read
In one paragraph

Article in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Emmanuel O OisakedeDepartment of Clinical Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer remains a major public health challenge in Nigeria, being the most commonly diagnosed cancer and the leading cause of cancer-related mortality among men. Despite recent improvements in cancer policies, registries, and selected diagnostic and treatment investments, access to timely, equitable, and guideline-concordant care remains limited. Current evidence indicates persistent late presentation, delays in diagnosis and staging, high out-of-pocket costs, and significant disparities in access to specialist services. Although curative treatments such as radical prostatectomy, radiotherapy, and brachytherapy are available in selected centres, many patients present with advanced disease or experience delays that limit their effectiveness. Consequently, androgen-deprivation therapy remains the predominant treatment modality. Improving outcomes requires strengthening the entire care pathway through early risk-based detection, efficient referral systems, faster pathology services, expanded financial protection, multidisciplinary management, and robust monitoring of treatment outcomes.

Indexed as

cancer care deliveryearly diagnosishealth systemsNigeriaProstate cancer

Identifiers

PMID42677115
PMCPMC13527800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.